Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) closed the day trading at $1.96 up 16.67% from the previous closing price of $1.68. In other words, the price has increased by $16.67 from its previous closing price. On the day, 0.63 million shares were traded. CRVS stock price reached its highest trading level at $2.0 during the session, while it also had its lowest trading level at $1.83.
Ratios:
For a better understanding of CRVS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on August 18, 2023, initiated with a Outperform rating and assigned the stock a target price of $7.
On May 27, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $10.Cantor Fitzgerald initiated its Overweight rating on May 27, 2021, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 06 ’24 when MILLER RICHARD A MD bought 577,634 shares for $1.73 per share. The transaction valued at 1,000,000 led to the insider holds 577,634 shares of the business.
Jones William Benton bought 20,000 shares of CRVS for $34,624 on May 06 ’24. The insider now owns 153,773 shares after completing the transaction at $1.73 per share. On May 15 ’23, another insider, Grais Linda, who serves as the Director of the company, bought 10,000 shares for $2.45 each. As a result, the insider paid 24,500 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRVS now has a Market Capitalization of 96115656 and an Enterprise Value of 67888688.
Stock Price History:
The Beta on a monthly basis for CRVS is 1.03, which has changed by -0.017543852 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, CRVS has reached a high of $4.19, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 9.51%, while the 200-Day Moving Average is calculated to be 9.13%.
Shares Statistics:
Over the past 3-months, CRVS traded about 241.08K shares per day on average, while over the past 10 days, CRVS traded about 344210 shares per day. A total of 49.04M shares are outstanding, with a floating share count of 36.90M. Insiders hold about 24.75% of the company’s shares, while institutions hold 17.98% stake in the company. Shares short for CRVS as of 1713139200 were 1365312 with a Short Ratio of 5.66, compared to 1710460800 on 1493650. Therefore, it implies a Short% of Shares Outstanding of 1365312 and a Short% of Float of 3.6999999999999997.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Corvus Pharmaceuticals Inc (CRVS) in the stock market.On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.15, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.13 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.5 and -$0.59 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.63, with 3.0 analysts recommending between -$0.45 and -$0.77.
